According to Cellectis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.572864. At the end of 2022 the company had a P/E ratio of -0.8974.
Year | P/E ratio | Change |
---|---|---|
2022 | -0.8974 | -67.62% |
2021 | -2.77 | -80.03% |
2020 | -13.9 | 95.35% |
2019 | -7.10 | -16.8% |
2018 | -8.54 | -17.98% |
2017 | -10.4 | 17.95% |
2016 | -8.83 | -81.69% |
2015 | -48.2 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | -2.31 | 304.06% | ๐ณ๐ฑ Netherlands |
![]() | -0.8345 | 45.67% | ๐บ๐ธ USA |
![]() | 15.8 | -2,853.36% | ๐บ๐ธ USA |
![]() | N/A | N/A | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.